New Launch25 Nov 2025, 09:05 am
Glenmark Pharmaceuticals Launches World's First Nebulized Triple Therapy for COPD
AI Summary
Glenmark Pharmaceuticals Ltd., a research-led global pharmaceutical company, has announced the launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world’s first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD). This breakthrough therapy combines three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. The nebulized triple therapy has demonstrated rapid improvement in lung function and better control of breathlessness among patients in a clinical study conducted in India.
Key Highlights
- Glenmark introduces the world's first nebulized fixed-dose combination of Glycopyrronium, Formoterol, and Budesonide for COPD treatment.
- This new therapy minimizes the burden of multiple medications and offers a simpler and more effective way to manage COPD.
- The nebulized triple therapy has shown rapid improvement in lung function and better control of breathlessness in a clinical study.
- Glenmark reinforces its position as a front-runner in respiratory innovation and its commitment to making advanced, affordable, and accessible solutions for patients.
- The company's Green House Gas (GHG) emission reduction targets have been approved by the Science Based Target initiative (SBTi).